PJC
ALNY icon

Phillip James Consulting’s Alnylam Pharmaceuticals ALNY Stock Holding History

Phillip James Consulting’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903 Hold
3
– – ﹤0.01% 282
2026
Q1 		$1K Buy
+3
New +$1.02K ﹤0.01% 253

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Phillip James Consulting's ALNY Position: Q2 2026 in Review

Phillip James Consulting held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 3 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #282.

Phillip James Consulting first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $1K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Phillip James Consulting held 3 shares of Alnylam Pharmaceuticals worth $903 as of Q2 2026.
  • Phillip James Consulting left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Phillip James Consulting's portfolio in Q2 2026, its #282 holding.
  • Phillip James Consulting first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Phillip James Consulting's Alnylam Pharmaceuticals position peaked at $1K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Phillip James Consulting's 13F filing for Q2 2026, filed 28 Jul 2026.